Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.


Make a donation


Canadian Statistics for Multiple Myeloma

Canada is one of the few countries in the world with a cancer registry system that allows cancer patterns to be monitored for the entire population.

The provincial, territorial and national cancer registries are important resources that can be used for research, knowledge exchange, planning and decision-making at all levels.

That said, when looking at this kind of data, it is important to keep in mind that statistics:

  • Are very general in nature;
  • Are based on large numbers of people with cancer and cannot predict exactly what might happen to any specific person;  
  • Can be based on data that may be several years old, and therefore not reflect the impact of more recent advances in early detection or treatment;
  • May not account for additional illnesses, individual responses to treatment, or other causes of death; and
  • Can vary widely within each stage of cancer.

According to the 2017 Canadian Cancer Statistics report released by the Canadian Cancer Society, the total new cases of multiple myeloma diagnosed annually in Canada are estimated at 2,900 (1,700 men and 1,200 women), which represents an incidence of 9.1 in 100,000 for men and 5.6 in 100,000 for women.

This corresponds to 1.6% of total new cases of cancer in men and 1.2% of total new cases of cancer in women. 

The total number of deaths from multiple myeloma were estimated at 1,450 (810 men and 640 women).

Understanding Incidence and Prevalence

INCIDENCE: The number of new cases diagnosed in a year.
MORTALITY: The number of deaths attributed to cancer.
PREVALENCE: The total number of cases of a disease at a specific time.

Prevalence is influenced by both the incidence and the mortality rate. Prevalence increases when survival rates increase, even though incidence remains the same. As multiple myeloma patients live longer, the prevalence increases.


Estimated new cases for multiple myeloma by sex and province, Canada, 2017

Men 1,700 210 170 45 55 700 400 40 45 10 25
Women 1,200 150 110 35 40 510 270 30 35 5 20
Total 2,900 360 280 80 95 1210 670 70 80 15 45

Estimated age-standardized incidence rates (ASIR) for multiple myeloma by sex and province, Canada, 2017

Men 9.1 7.9 9.3 8.0 8.8 9.8 8.8 8.5 8.0 10.8 8.1
Women 5.6 5.2 5.4 5.8 5.3 6.1 5.0 5.7 5.3 6.4 5.0


Prevalence of multiple myeloma by time since diagnosis and sex, Canada, January 1, 2009

(Diagnosed since 1999)

(Diagnosed since 2004)

(Diagnosed since 2007)

Men 4,100 3,110 1,560
Women 3,360 2,510 1,320
Total 7,460 5,615 2,885

Source: Canadian Cancer Society's Advisory Committee on Cancer Statistics, Canadian Cancer Statistics 2017. Toronto, ON: Canadian Cancer Society; 2017.